Isomorphic Labs, the DeepMind‑derived AI‑drug company, secured a $2.1 billion Series B led by Thrive Capital. The round also drew Abu Dhabi’s Sovereign AI fund, Singapore’s Temasek, Alphabet’s GV and MGX. The injection follows a $600 million raise last year and positions the company to expand its AI‑driven discovery pipeline for the future drug development efforts globally today.

Founded in 2021, Isomorphic spun out of Google DeepMind to focus on drug design rather than general AI research. Colin Murdoch, now president, and DeepMind CEO Demis Hassabis steered the split, noting that chemists and biologists—absent a clear career path at DeepMind—were essential for the new mission to accelerate therapeutic discovery across healthcare sectors.

The firm builds a drug‑discovery platform powered by AlphaFold, DeepMind’s protein‑folding AI. By translating protein structures into actionable targets, Isomorphic competes with players like OpenAI, which unveiled a life‑sciences model earlier this year. The technology promises to shrink early‑stage research timelines for pharmaceutical companies seeking faster drug candidate development and clinical validation streams today and and.

Strategic partnerships with Eli Lilly and Novartis give Isomorphic access to established drug pipelines, while the company has begun pre‑clinical trials on its first candidates. With the new capital, it aims to advance these compounds into clinical testing, potentially reshaping how biologics are identified and developed for the future of therapeutic innovation within the global pharma.